Clinical trial
SB-681323 In Subjects With Rheumatoid Arthritis
NCT00320450 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00320450 |
|---|---|
| Title | SB-681323 In Subjects With Rheumatoid Arthritis |
| Official title | A Randomised, Parallel Group, Placebo-controlled, Double Blind Study to Assess the Safety and Tolerability of SB-681323 at 7.5mg Daily Dose for 28 Days and Its Effect on the Levels of Serum C-reactive Protein (CRP) in Subjects With Rheumatoid Arthritis (RA) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Drug |
| Interventions | SB-681323 |
| Enrollment | 78 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | May 3, 2006 |
| Last update posted | Nov 4, 2013 |
| Countries | Denmark, Germany, Hong Kong, Italy, Norway, Poland, Spain, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: